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Abstract 
Excitatory activity in the CNS is predominately mediated by L-glutamate through 
several families of L-glutamate neurotransmitter receptors.  Of these, the N-methyl-D-
aspartate receptor (NMDAR) family has many critical roles in CNS function and in various 
neuropathological and psychiatric conditions. Until recently, the types of compounds 
available to regulate NMDAR function have been quite limited in terms of mechanism of 
action, subtype selectivity, and biological effect. However, several new classes of NMDAR 
agents have now been identified that are positive or negative allosteric modulators (PAMs 
and NAMs, respectively) with various patterns of NMDAR subtype selectivity. These new 
agents act at several newly recognized binding sites on the NMDAR complex and offer 
significantly greater pharmacological control over NMDA receptor activity than previously 
available agents. The purpose of this review is to summarize the structure-activity 
relationships for these new NMDAR modulator drug classes and to describe the current 
understanding of their mechanisms of action.  
  
1. Introduction 
N-methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels which, along 
with AMPA and kainate receptors, are activated by the brain’s primary excitatory 
neurotransmitter, L-glutamate1-4.  The NMDA receptors (NMDARs) are known for their 
prominent roles in synaptic plasticity and in a number of neurological and psychiatric 
disorders including pain, stroke, epilepsy, schizophrenia, post-traumatic stress disorder, 
depression and various neurodegenerative diseases such as Alzheimer’s and Parkinson’s5-11.  
Thus, NMDARs are a desirable pharmacological target and yet, few NMDAR-based drugs 
have been successful in the clinic due to adverse side effects from off-target activity or adverse 
effects from excessive NMDAR inhibition. Despite limited success to date, there remains 
significant potential for the development of useful agents that modify NMDAR activity.  
Since the different NMDAR subtypes have significantly varied physiological properties and 
anatomical distributions, agents that act at distinct NMDAR subtypes are expected to have 
markedly different therapeutic and adverse effects.  Furthermore, the relatively recent 
identification of several distinct families of positive and negative allosteric modulators has 
revealed that there is a great potential to develop agents with highly specific activities that 
should provide advantages over prior agents12, 13.  These allosteric modulators differ from 
each other in several functional properties and in their subtype selectivity, thus greatly 
expanding the repertoire of NMDAR pharmacological modulation. In addition to developing 
therapeutics for the above-mentioned diseases, these agents are also powerful tools for 
defining the function of NMDARs, and their subtypes, in CNS function. These newer agents 
act at sites distinct from where the well characterized NAM ifenprodil is thought to bind14. 
As the pharmacology of ifenprodil-related agents has been well described over the years15, 16, 
  
this review will focus mostly on the recent studies regarding compounds acting at novel 
allosteric sites that are distinct from the ifenprodil site.   
The NMDAR is a heterotetrameric complex composed of subunits arising from seven 
homologous genes: GluN1, GluN2A-GluN2D and GluN3A-GluN3B3, 4. These subunits form 
an ion channel pore through the plasma membrane that is permeable to Na+, K+, and Ca2+ and 
gated by the simultaneous binding of L-glutamate to the GluN2 subunit and glycine (or D-
serine) binding to GluN1 or GluN3 subunits.  The majority of NMDARs are believed to 
contain two GluN1 subunits and two GluN2 subunits.  NMDAR subunits have a modular 
structure with distinct domains (Figure 1): the extracellular amino-terminal domain (ATD) – 
a modulatory domain which can bind zinc in the case of GluN2A, the ligand binding domains 
(LBD) which bind L-glutamate (GluN2A-D) or glycine (GluN1 or GluN3), the 
transmembrane domains (TMD) which forms the pore, and an intracellular C-terminal 
domain.  The ATD is a bi-lobed, clamshell-like structure that can be either open or shut; the 
shut conformation inhibits receptor function14, 17. The LBD forms a similar bi-lobed structure 
where the two extracellular segments (S1 and S2) form the two halves of the clamshell 
structure.  S1 is the peptide sequence between the ATD and the first membrane-associated 
domain (M1) and S2 is the segment between the third and fourth membrane-associated 
domains (M3 and M4).  Agonist binding in the center cavity of the LBD stabilizes a closed 
conformation whereas competitive antagonist binding prevents this closure18.  The combined 
closing of the GluN1 and GluN2 LBDs allosterically transmits a change in the TMD 
corresponding to a higher probability of an open channel. 
Allosteric modulators have several distinct advantages for the development of suitable 
therapeutic agents compared to the other classes of NMDAR pharmacological agents 
(agonists, competitive antagonists, and channel blockers). Enhanced subtype-selectivity 
  
generally minimizes off-target activity and unwanted side effects, and allosteric modulators 
bind to regions other than the highly conserved ligand binding sites or the channel pore.  Thus, 
allosteric agents have greater potential for subtype-selectivity as has been found already.  
NAMs also have the potential of maximally inhibiting less than 100% of the agonist response, 
thus preserving some function and avoiding excessive blockade. Therefore, such partial 
NAMs should have a better safety profile than competitive antagonists and channel blockers 
that can potentially eliminate all activity.  A partial agonist at the ligand binding site also 
promotes intermediate activity levels, but unlike a NAM, a partial agonist could activate 
otherwise inactive receptors. Positive allosteric modulators (PAMs) also offer distinct 
advantages.  For the treatment of NMDAR hypofunction as in schizophrenia, or possibly in 
other cases of cognitive dysfunction, augmenting NMDAR activity would be expected to 
restore proper function by increasing the activity of weakly-activated NMDAR-mediated 
signals.   In contrast to PAMs, an NMDAR agonist would activate both appropriate and 
inappropriate receptors and thus increase system noise and potentially cause excitotoxicity. 
Given these advantages of NMDAR allosteric agents, and the recent demonstration of 
multiple new classes of allosteric agents, there has been a resurgence in NMDAR drug 
development targeting PAMs and NAMs.  This review will focus mostly on the recent studies 
regarding compounds acting at novel allosteric sites located outside of the ATD on the 
NMDAR.  Structure-activity relationship (SAR) studies used in the development of these 
allosteric modulators and mechanistic studies aimed at identifying their binding sites and 
mode of action will be discussed.  
 
2. Steroidal Based NMDAR NAMs and PAMs: Neurosteroids and Cholesterols 
  
2.1 Neurosteroids 
Neurosteroids and related cholesterols were among the first agents to be identified that 
can allosterically modulate ionotropic glutamate and GABA receptors19, 20.  Interestingly, 
some of these compounds are endogenous to neural tissue and they can display both PAM 
and NAM activity at NMDARs.  Thus, they may represent natural ligands used to modulate 
NMDAR function.  Using these steroid structures as starting points, medicinal chemistry 
efforts have gone on to identify synthetic agents which are now lead compounds being studied 
for different therapeutic applications. Of the various neurosteroids, two of the most 
extensively studied for their activity at NMDARs are pregnenolone sulfate 1 (20-oxo-5-
pregnen-3β-yl sulfate, commonly abbreviated to PS), which displays both PAM and NAM 
activity, and pregnanolone sulfate 2 (20-oxo-5β-pregnan-3-yl sulfate, commonly 
abbreviated to 35S or PAS), which is a NAM (Figure 2a). 
2.1.1 Neurosteroid PAM & NAM SAR 
PS is a potentiator of NMDARs and an inhibitor of AMPA (AMPAR), kainate (KAR) 
and GABA-A receptors21. PAS, on the other hand, displays inhibitory activity at NMDARs, 
KARs, and AMPARs21. This was found to be as a result of their respective geometry. PS has 
a more planar geometry than PAS as a result of the double bond in the second ring (Figure 
2b). Investigations into the effect of the geometry were carried out with a number of 
derivatives with and without a double bond. It was found that more planar compounds tended 
to have PAM activity and those with a more ‘bent’ structure were generally inhibitors22. A 
summary of the most important SAR observations regarding PAS and PS derivatives can be 
found in Figure 2b. In general, some modifications of PAS did result in increased NAM 
potency, whereas PS PAM activity was not significantly improved. Both PAS and PS require 
  
a charged group at C3; PS PAM activity is dependent on a negatively charged substituent, but 
in the case of PAS, the group can be positively or negatively charged. Replacement of the 
sulfate group with uncharged groups such as hydrogen or formate eliminates PAM activity in 
PS derivatives and NAM activity in PAS derivatives, while substitution with dicarboxylic 
acid esters of varied length, from hemioxylate to hemiglutarate, generally maintains activity23. 
Replacement of the C3 sulfate of PAS with positively charged L-argininyl or 4-
(trimethylammonio)butanoyl increases inhibitory activity24. Although additions to ring D of 
PS reduced activity, some additions to ring D of PAS increased activity significantly25,26. In 
particular, compound 3, with an isobutyl chain instead of the acetyl group of PAS, has an IC50 
of 90 nM at GluN1/GluN2B receptors27a. It was concluded that the inhibitory potency was 
directly related the lipophilicity of the compounds. Some of this requirement for lipophilicity 
may be needed for access to the PAS binding site; there is evidence that PAS can enter the 
membrane to get to its binding site24. 
  
 
Figure 2: (a) Lead compounds 1 (PS) and 2 (PAS); (b) General SAR; (c) NAM 3. 
 
2.1.2 Neurosteroid PAM activity and mechanism of action 
PS inhibits GABA-A, glycine, AMPA and kainate receptor responses as well as those 
of NMDARs containing GluN2C and GluN2D subunits22-24. In addition to this general 
inhibitory activity, PS potentiates agonist responses at neuronal NMDARs25, 26 and NMDARs 
that have GluN2A or GluN2B subunits24, 27b. Further studies demonstrated that PS has both 
PAM and NAM activity at each of the four GluN1/GluN2A-D receptors with PAM activity 
being dominant at GluN2A and GluN2B-containing receptors and NAM activity 
  
predominating at receptors containing GluN2C or GluN2D.  When co-applied with agonist, 
PS potentiates steady-state responses of GluN1/GluN2A and GluN1/GluN2B receptors while 
inhibiting activity at GluN1/GluN2C and GluN2D receptors24.   However, when PS is pre-
applied and rapidly replaced by agonist (sequential application), PS displays potentiating 
activity of the initial agonist response at GluN2C and GluN2D-containing receptors and 
enhanced potentiating activity at GluN2A- and GluN2B-containing receptors27b.  This is 
interpreted as reflecting the rapid loss of inhibitory activity and the persistence of PS 
potentiating activity when switching from PS to agonist at each of the four GluN1/GluN2 
receptors. Taking advantage of these different drug application paradigms to distinguish 
NAM and PAM activity, PS was found to potentiate the different NMDARs with similar 
EC50s (~80 µM) but with greater maximal potentiation at receptors containing GluN2A or 
GluN2B subunits.  In contrast, PS inhibitory activity was estimated to be several fold more 
potent at GluN2C and GluN2D than at GluN2A and GluN2B27b.  
Under some conditions, PS appears as a weakly effective PAM.  PS potentiation of 
GluN1/GluN2A and GluN1/GluN2B receptor responses declines during L-glutamate 
application, a response described as “dis-use dependent” potentiation28. This may reflect a 
higher affinity of PS for the resting receptor state than the activated state and may also 
contribute to the greater potentiation seen with sequential PAM/agonist application mentioned 
above.  Such dis-use dependency should result in greater potentiation of phasic, synaptic 
glutamate-mediated NMDAR responses over tonically-activated extrasynaptic NMDAR 
responses.  However, this effect may be offset by reduced ability of PS to potentiate GluN2B-
mediated responses to high agonist concentrations. PS causes a small increase in agonist 
potency at GluN2B-mediated responses24, 28.  Accordingly, at high L-glutamate 
concentrations, which would obscure a potentiating effect due to increased agonist potency, 
  
there is relatively little PS potentiation of GluN2B-mediated responses. Reduced PS 
potentiation in the presence of high L-glutamate concentrations is also seen for neuronal 
NMDAR responses26.  Since synaptic responses see saturating agonist concentrations, while 
extrasynaptic receptors experience lower agonist concentrations, one might expect PS to 
preferentially potentiate extrasynaptic over synaptic GluN2B-containing receptors. Other 
than the small effect on L-glutamate potency at GluN2B-containing receptors, PS generally 
has little effect on agonist EC50 and can potentiate responses due to saturating concentrations 
of agonist23, 24, 26. Thus, PS potentiation must have additional mechanisms to increase 
NMDAR responses other than by increasing agonist potency. 
PS slows the rates of both NMDAR desensitization and deactivation.  In whole cell 
recordings of recombinant GluN1/GluN2A and GluN1/GluN2B receptors, PS slowed the 
macroscopic desensitization rate but did not change the extent of desensitization29. PS also 
slowed the deactivation time that is related to L-glutamate unbinding28, 29.  Consistent with 
these findings, PS also prolongs NMDAR synaptic currents29, 30, which are determined by 
NMDAR deactivation time31.  Several of the physiological properties of PS along with other 
allosteric modulators are summarized in Table 1.  Potencies of representative NAMs and 
PAMs are summarized in Tables 2 and 3, respectively. 
NMDAR channel properties, as expected, are also changed by neurosteroids. Using the 
rate of MK-801 channel blockade as an index of open channels, PS increases open channel 
probability of GluN1/GluN2B receptors28.  Consistent with this finding, at single channels in 
isolated patches, PS increases the frequency of channel openings, has a small, variable effect 
on neuronal NMDAR mean channel open time, and has no effect on single channel 
conductance26, 32.  Similar results are found using cell-attached patches in which the receptor 
sees a relatively intact intracellular environment, except that in this condition, PS produces a 
  
more robust increase in the mean open time26, 33.  Thus, the effect of PS on mean open time 
depends upon an undiluted intracellular environment, but the effect on channel opening 
frequency does not. These results are consistent with the observation that the rapid loss of PS 
potentiation of NMDAR responses in outside-out patches is slowed by protein phosphatase 
inhibitors34.  
In addition to the NMDAR PAM activity of PS, there is also evidence for direct receptor 
activation when measuring calcium mobilization or ligand-induced receptor trafficking35, 36.  
In this case, PS could possibly be acting as an agonist for mGluR-like activity of NMDARs36, 
37.  Further SAR characterization of this agonist activity of PS would be interesting as it may 
be possible to have biased signaling of mGluR-like activity.  Since the structurally related 
compound PAS can form nanoparticles38, the role of possible PS nanoparticles in this 
additional activity may need to be evaluated.  
2.1.3 Neurosteroid NAM activity and mechanism of action 
PAS, like PS, has a general inhibitory action at ionotropic glutamate receptors - 
AMPARs, KARs, and NMDARs21, 23, but without the additional NMDAR PAM activity.  The 
inhibitory activity of PAS is voltage-independent and non-competitive with glutamate and 
glycine; it reduces the maximal agonist responses at each of the four GluN1a/GluN2 subtypes 
while minimally changing agonist potency24, 39.  PAS inhibition is also use-dependent with no 
evidence of binding to the resting state of the receptor in the absence of agonist39. 
Accordingly, PAS displays less inhibition of synaptic NMDAR responses than of steady-state 
NMDAR responses.  This property could be useful in that PAS may weakly inhibit synaptic 
NMDAR currents while providing greater inhibition of tonically-activated extrasynaptic 
NMDAR currents that are thought to occur in pathological conditions.  Among structural 
variations of the PAS structure, some agents were found to display use-independent inhibition 
  
in contrast to the use-dependent actions of PAS.  Thus, these agents would be expected to 
differ in their actions on NMDAR responses due to phasic/synaptic or tonic/extrasynaptic 
activation40. 
In contrast to PS potentiation, PAS inhibition of GluN1/GluN2A receptors in cell-
attached patches has no effect on mean open time but instead decreases open probability by 
increasing mean closed time by specifically increasing the duration of long-lived closed states 
related to desensitization41. Interestingly, under some recording conditions, the PAM PS can 
instead inhibit GluN1a/GluN2A responses. In this case, inhibition is associated with a 
reduction in mean open time and no change in mean closed time33. Thus, the inhibitory actions 
of PS and PAS at GluN1a/GluN2A receptors appear to have distinct mechanisms. 
2.1.4 Neurosteroid NAM and PAM Binding Sites 
The neurosteroid NAM and PAM binding sites are thought to be located extracellularly 
and to be distinct from each other27b, 42; neurosteroid NAMs do not display competitive 
interactions with neurosteroid PAMs42.  Neurosteroids are able to access their modulatory 
binding site via the membrane. In cell-attached patch recordings, PS administration to the 
outside of the cell, and outside of the patch pipette, can potentiate NMDAR responses under 
the pipette26. PS is not likely to be acting at an intracellular site since intracellular injections 
of PS do not reduce potentiation to externally applied PS27b, 42. Thus, PS may be accessing the 
receptor through a membrane route as has been suggested for inhibitory neurosteroids40.  From 
this work, the neurosteroid binding sites are thought to be extracellular and may involve the 
transmembrane region of the receptor as has been suggested for GABA-A receptors43. 
The precise identification of the binding site responsible for PS PAM activity remains 
unknown but is thought to involve S2 (extracellular loop between M3 and M4) and M4. PS 
  
displays GluN2C-like inhibitory activity at chimeras wherein the GluN2A sequence has the 
S2 domain sequence (plus most of M3 and M4) replaced by GluN2C's corresponding 
sequence27b.  Similarly, it was found that a GluN2D construct in which the 84 amino acids 
containing the C-terminal third of S2 and M4 is replaced with the corresponding sequence 
from GluN2B displays GluN2B-like PS PAM activity44.  Replacing both of the S2 and M4 
portions in GluN2D with the corresponding sequence from GluN2B is necessary for PAM 
activity in the chimeric construct. Conversely, replacing this segment in GluN2B with that 
from GluN2D eliminated PAM activity (but did not generate GluN2D-like NAM activity of 
PS or PAS).  Thus, subunit-specific PS PAM activity appears to be defined by the C-terminal 
third of the S2 domain and M4 while PS/PAS NAM activity may involve additional upstream 
regions.  This result is consistent with point mutation results; mutating D813A/D815A in 
GluN2A, which immediately precedes M4, prevents PS potentiation, but not PAS inhibition45.  
Conversely, GluN2A-A651T (the homologous site of the Lurcher mutation at the end of the 
highly conserved SYTANLAAF sequence in the M3/S2 linker region) reduces PAS inhibition 
but has no effect on PS potentiation.  Likewise, mutations in this region of GluN1 and 
GluN2B, alter PAS potency38.  Thus, the PAS NAM binding site may be at the extracellular / 
membrane interface of M3/S2 or require allosteric interactions at this location.   
2.2 Cholesterol derivatives  
2.2.1 Cholesterol derivative PAM and NAM SAR 
The endogenous compound 24(S)-hydroxycholesterol 5 (24(S)-HC) has a structure and 
PAM activity similar to that of PS but is more potent (EC50 ~ 1 µM) and thought to have a 
different binding site (Figure 3)46. Receptor chimera studies indicate that PS requires 
transmembrane domains and some of the LBD whereas 24(S)-HC primarily requires just the 
transmembrane domains47.  The concept of different binding sites is also consistent with the 
  
observation that 24(S)-HC preapplication occludes the activity of the 24(S)-HC derivative 
SGE-201 (6, Figure 3), but not that of PS.  While endogenous cholesterol 4, from which 24(S)-
HC is derived (Figure 3), helps to maintain baseline NMDAR responsiveness48, it does not 
have potent PAM activity.  24(S)-HC is selective for NMDARs over AMPA and GABA-A 
receptors but does not distinguish between the four GluN1/GluN2 receptors. Further 
modification of the D ring alkyl chain by adding two methyl groups at C24 together with the 
hydroxyl group (SGE-201 6) increases PAM potency nearly ten-fold over 24(S)-HC.  In 
contrast, 25-hydroxycholesterol (25-HC) (7) has very weak PAM activity and instead non-
competitively blocks the potentiation by 24(S)-HC and SGE-201, but not by PS49.  This result 
again suggests that PS and 24(S)-HC have distinct binding sites and that 24(S)-HC and 25-
HC may also have distinct binding sites. 
 
Figure 3: Structures of cholesterol (4), 24(S)-HC (5), SGE-201 (6) and 25-HC (7). 
 
  
2.2.2 Cholesterol PAM & NAM mechanism of action 
The mechanism of action of SGE201 and 24(S)-HC is to increase open channel 
probability, as indicated by an acceleration of the rate of MK-801 open channel blockade of 
NMDARs.  Also, like PS, SGE201 can access its binding site from the outside through the 
plasma membrane but not from the intracellular side49.  The onset and offset of PAM activity 
is very slow, which is consistent with SGE201 accessing its binding site through the 
membrane.  PAM activity is associated with a small increase in L-glutamate potency, but this 
may be due to an increase in agonist efficacy rather than an increase in agonist affinity.  
3. Non-steroidal NMDAR NAMs 
3.1 GluN2A-selective NAMs 
3.1.1 Sulfonamide series   
Bettini and colleagues50 identified the first highly selective non-competitive GluN2A 
inhibitors which were also the first ligands later reported to bind at the LBD GluN1/GluN2 
dimer interface51. The prototype is TCN-201 8 (Figure 4a).  Although the inhibitory activity 
of TCN-201 is reversed by high concentrations of glycine in a manner largely consistent with 
a competitive antagonist50, Schild analysis indicates that the compound is a non-competitive 
antagonist that reduces glycine and D-serine affinity52, 53. In the initial study, five lead 
compounds were identified in a high-throughput screen using a FLIPR®/Ca2+ assay, with all 
fully blocking human recombinant GluN2A receptors. A number of structurally similar 
analogues were identified and tested in order to gather SAR information. TCN-201 (8) was 
one of the lead compounds, and one of the more successful of the series, displaying 
submicromolar potency (IC50 ~ 100 nM) with >300-fold selectivity for GluN2A over 
GluN2B, GluN2C, and GluN2D.50, 53 
  
3.1.1.1 Sulfonamide series NAM SAR  
Replacing ring B of TCN-201 with various cycloalkyl or heteroaryl moieties had little 
effect on activity, perhaps indicating a larger space was available than the one currently 
occupied (Figure 4a). With respect to ring C, the 3-Cl was recently shown to be essential with 
its removal drastically reducing activity54. The 4-F on the other hand, was found to be 
superfluous with its removal marginally increasing activity. The 3-Br analogue (9, 
IC50=204nM) was reportedly 2.5-fold more potent than TCN-201 (IC50=512nM) against 
GluN1/GluN2A receptors (Figure 4b).      
Although TCN-201 has been used in a small number of studies to investigate the role of 
GluN2A in physiological processes55-57, its use as a tool in native systems has been limited 
due to poor aqueous solubility. Consequently, a SAR study was initiated with the aim of 
improving potency and drug-like properties whilst maintaining GluN2A selectivity58. 
Keeping the phenylsulfonamide ring constant, it was found that replacing the phenylhydrazide 
portion of the molecule with a 2-(methylthiazol-5-yl)methanamine moiety did not 
significantly affect activity (Figure 4c). To lower lipophilicity, the central benzene ring (A in 
Figure 4a) was replaced with either a pyrazine or pyridine ring. Encouragingly, the resultant 
analogues displayed significantly improved potency and the pyrazine-containing derivatives 
had superior pharmacokinetic properties. Further observations included: (i) an improvement 
in potency on addition of a methyl group to the pyrazine ring (i.e. R4 = Me), (ii) swapping the 
3-Cl and 4-F substituents on the benzenesufonamide ring resulted in a large drop in activity, 
and (iii) alkylation of the sulfonamide nitrogen was detrimental (R5 = Me). Considering 
GluN2A potency, selectivity, solubility and other pharmacokinetic properties, MPX-004 10 
(IC50 = 79 nM) and MPX-007 11 (IC50
 = 27 nM) were selected for further investigation. 
  
Although MPX-004 had a lower antagonist potency at GluN2A than MPX-007, it was more 
selective over the other GluN2 subtypes of the NMDAR (Figure 4c).  
 
Figure 4: (a) Structure of lead compound 8 (TCN-201); (b) compound 9; (c) Most 
selective compound for GluN2A (9, MPX-004) and most potent compound at GluN2A (10, 
MPX-007). 
 
3.1.1.2 Sulfonamide series: LBD-interface NAM binding site and mechanism of action 
The structural basis of both glycine reversal of NAM activity and GluN2A selectivity 
of TCN-201 and MPX-004/MPX-007 are now understood51. Site-directed mutagenesis and 
  
crystallography studies indicate that the TCN-201 binding site is located at the dimer interface 
between the two ligand binding domains (Figure 5) at a site partially overlapping with the 
PAM GNE-6901 binding site (discussed below).  In the binding pocket, both TCN-201 and a 
related compound (compound 6 from Bettini and colleagues50) were found to fold back on 
themselves with stacking of the middle and the halogenated rings51, 59 (Figure 6).  The middle 
ring also interacts with the GluN2A-specific residue V783 which accounts for TCN-201’s 
selectivity; this residue is replaced by phenylalanine in GluN2B and leucine in GluN2C and 
GluN2D which sterically hinder NAM binding.  When the NAM is bound, GluN2A V783 is 
displaced and, in turn, interacts sterically with GluN1 F754.  This latter interaction is 
unfavorable and can be accommodated by glycine unbinding and opening of the GluN1 LBD 
to allow GluN1 F754 to move away from GluN2A V78351.  Thus, the NAMs stabilize the 
open, inactive GluN1 LBD conformation. Using a GluN1 construct in which the LBD is 
locked in the closed, active conformation by incorporating disulfide bonds across the LBD 
cleft, confirms that opening of the GluN1 LBD is necessary for TCN-201/MPX-004/MPX-
007 inhibition51. 
3.2. GluN2C/D selective NAMs 
3.2.1 The quinazoline-4-one series  
A series of non-competitive inhibitors containing a quinazoline-4-one ring system (e.g. 
QNZ46, 15, Figure 7d) was found to be selective for GluN2C/D- over GluN2A/B-containing 
NMDARs60. Compounds with an (E)-3-phenyl-2-styrylquinazoline-4(3H)-one backbone 
were identified during a high throughput screen looking for allosteric NMDAR antagonists. 
Lead compounds 12 and 13 displayed IC50 values of 9 μM and 5 μM against GluN2D, 
respectively (Figure 7a). However, these hits were structurally similar to the non-competitive 
AMPAR antagonist CP-465022 (14)61 so selectivity over AMPARs was predicted to be an 
  
issue (Figure 7b). When tested, both compounds proved inactive at kainate receptors (KARs), 
but had only 4 to 5-fold selectivity for NMDARs over AMPARs.  
3.2.1.1 Quinazoline series NAM SAR 
An SAR study was subsequently conducted with the aim of optimizing potency and 
selectivity toward GluN2D containing NMDARs. The study consisted of making systematic 
modifications to the ring substituents; the optimal substituent and position was determined for 
each of the three rings in turn (Figure 7c). Analogues without substituents on any of the three 
rings were inactive at both NMDARs and AMPARs. The optimal substituent on ring A was 
found to be a para-carboxylic acid (R3 = p-CO2H), regardless of what substituents were 
present on the other two rings. With respect to ring B, a nitro group proved best with the ortho 
and meta analogues (R4 = o- or m-NO2) being roughly equipotent versus GluN2D. 
Interestingly, the para-nitro derivative (R4 = p-NO2) was less active but displayed better 
selectivity for GluN2D over GluN2A and AMPARs. Keeping the favored carboxylate and 
nitro groups constant on rings A and B (R3 = p-CO2H, R
4 = m-NO2), attention turned to 
optimizing ring C. Substitution at the 6-position with either a methoxy or iodo group proved 
most beneficial to potency and selectivity (R5 = 6-OMe or 6-I). Having extensively explored 
the substitution on each ring, the effect of modifying the backbone itself was examined. 
Removal of ring A resulted in complete loss of inhibition while reduction of the styryl linker 
to the corresponding phenethyl analogue reduced potency 10-fold. Replacement of ring A 
with larger aromatic systems was tolerated to some extent, suggesting space in the binding 
pocket for a larger hydrophobic group. From the series, compounds 15 (QNZ46) and 16 were 
the most potent and selective compounds for GluN2C/D-containing NMDARs when tested 
using a two-electrode voltage clamp (TEVC) assay (Figure 7d); 15 had an IC50 value of 3 μM 
at GluN2D and 6 μM at GluN2C in comparison to >200 μM at GluN2A/B and AMPARs, 
  
while 16 had an IC50 of 2 μM at GluN2C and 1 μM at GluN2D and is over 300-fold selective 
for GluN2D over GluN2A/B and AMPARs.  
 
Figure 7: (a) Lead compounds 12 and 13; (b) CP 465022 (14); (c) General SAR observations; 
(d) Representative compounds 15 (QNZ46) and 16. 
Although at times it was difficult to pin down which substitution patterns were 
controlling potency and selectivity, the fact that there were variations in selectivity suggests 
  
the potential to achieve selectivity over GluN2A/2B-containing NMDARs, AMPARs and 
KARs. Overall the series indicated a promising starting point for achieving potent NAMs that 
were selective for GluN2C and GluN2D versus GluN2A and GluN2B. 
 
3.2.1.2 Quinazoline NAM series: QNZ46 binding site and mechanism of action 
The subtype-selectivity of QNZ46 is due to residues located in S2, but it has not been 
possible to define the binding site precisely.  By taking advantage of the differential activity 
of QNZ46 on GluN2A and GluN2D, chimera and point mutations studies were able to identify 
a cluster of residues in the GluN2 S2 domain that are important for QNZ46 activity62. Since 
these residues have a relatively weak effect on QNZ46 activity, it was suggested that these 
residues may not be directly contributing to the binding site but may instead be contributing 
to QNZ46’s actions. These critical residues are located on the lower portion of the S2 domain 
near the membrane and the linker sequences between the LBD and the TMDs.  These residues 
are thus positioned where they may influence channel gating through interacting with the 
linkers to M1 and M3 (Figure 8).  It is possible that QNZ46 binds in a site that is conserved 
among subunits, but the ability of binding to transduce inhibition involves GluN2-specific 
residues downstream. 
QNZ46 NAM activity is mechanistically distinct from the TCN-201-related GluN2A 
inhibitors discussed above.  Unlike TCN, QNZ46 has minimal and distinctly different effects 
on agonist potency62. Whereas TCN inhibits by reducing glycine potency, QNZ46 at 
GluN1/GluN2D receptors increases L-glutamate potency 2-fold and has a smaller effect at 
increasing glycine potency. A notable feature of QNZ46 inhibition that provides a hint as to 
the inhibitory mechanism is the requirement of L-glutamate binding. QNZ46/glycine pre-
incubation followed by L-glutamate plus QNZ46/glycine application results in a transient 
  
peak response followed by a steady-state inhibition.  These and other experiments led to the 
idea that L-glutamate, but not glycine, is necessary for QNZ46 binding.  Also, QNZ46 
unbinding may be partially necessary for L-glutamate unbinding since QNZ46 presence slows 
receptor deactivation due to L-glutamate (but not glycine) removal.  This property can account 
for the 2-fold increase in L-glutamate potency by QNZ46.  These findings led to the model 
that QNZ46 inhibits NMDAR function by binding somewhere in/near the lower lobe of S2 at 
a binding site exposed by L-glutamate binding.  LBD cleft closure due to L-glutamate binding 
is thought to pull on the LBD’s S2-M3 linker to open the channel.  NAM binding in this region 
may block the ability of the S2-M3 linker to move in response to LBD cleft closure thus 
keeping the channel closed and at the same time stabilizing the closed LBD conformation.  
This mechanism thus accounts for the ability of a NAM to increase agonist potency while 
blocking channel activation. 
 
3.2.2 The Pyrazoline series 
The pyrazoline scaffold was found to have GluN2C/D NAM activity from a high 
throughput screen. The initial hit, 17 (Figure 9a), had an IC50 of 2.7 and 5.4 µM at GluN2D 
and GluN2C respectively, with marginal selectivity over the other NMDAR subunits (IC50 = 
78 µM at GluN2A and 19 µM at GluN2B)63.  As for QNZ46, residues in the S2 domain near 
the membrane are important for the subtype-selectivity of these compounds, but the precise 
binding site remains to be defined. An in-depth SAR study resulted in the development of 
several compounds with IC50 values in the 100-500 nM range with 50- to 200-fold selectivity 
for GluN2C- and GluN2D- over GluN2A or GluN2B-containing NMDARs.64 These 
compounds also showed minimal off-target activity when tested against AMPA, kainate, 
glycine, serotonin, GABA, and nicotinic receptors.  
  
3.2.2.1 The Pyrazoline series: SAR 
During SAR studies, systematic modifications were made to rings A, B, and C of 17 
(Figure 9b). With respect to ring A, electron-withdrawing groups at the para- position were 
found to bestow the best activity, with a chloro substituent (R1 = Cl) proving optimal. 
Replacement of ring A with various heterocyclic rings including furan and thiophene reduced 
activity drastically. The introduction of electron-withdrawing substituents to ring B also 
enhanced activity with meta- and para- substituted derivatives (e.g. R2 = m- or p-Cl) proving 
roughly equipotent. In contrast, the addition of substituents to ring C (R3) had a detrimental 
effect, although the resultant analogues showed variability with regard to selectivity for 
GluN2A over GluN2B containing receptors, thereby suggesting a potential for optimizing 
selectivity. Having thoroughly investigated rings A, B, and C, attention was focused on the 
acyl chain. Incorporation of a double bond had little effect on potency as did extension of the 
chain from succinic (n = 1) to glutaric acid (n = 2). Swapping the terminal acid (R4 = CO2H) 
for a hydroxymethyl (R4 = CH2OH) greatly improved selectivity for GluN2D over GluN2A 
whilst maintaining similar activity at the other NMDAR subtypes. However, replacement of 
the carboxylic acid with an amide (R4 = CONH2) reduced both potency and selectivity while 
a fluoro group (R4 = F) resulted in all activity being lost. Compound 18 (DQP-26) is 
representative of one of the more successful compounds with IC50s of 0.77 and 0.44 µM at 
GluN2C and Glu2ND respectively, with ca. 50-fold selectivity over GluN2A- and GluN2B-
containing receptors. Enantiomeric separation showed that the S-enantiomer of 18 was 11-
fold more potent at GluN2D than the R-enantiomer and had improved selectivity for GluN2C 
and GluN2D over GluN2A and GluN2B. 
  
 
Figure 9: (a) Lead compound 17; (b) General SAR observations; (c) Representative 
compounds 18 (DQP-26) and 19 (DQP-1105). 
3.2.2.2 The Pyrazoline series: DQP-1105 binding site and mechanism of action 
DQP-1105 (19, Figure 9) and QNZ46 partially share the same structural determinants 
in the receptor that are responsible for the GluN2C/GluN2D selectivity of these compounds62, 
63.  Thus, they may have overlapping binding sites and a similar mechanism of action.  From 
GluN2A/GluN2D chimera studies, sequences in the N-terminal third of the S2 domain are 
  
necessary for DQP-1105 inhibitory activity.  Of the GluN2D-specific residues in this region, 
mutating Q701 and L705 to the corresponding amino acids in GluN2A significantly reduce 
inhibition by DQP-1105 and QNZ46.  Another similarity between these two classes of 
compounds is that their binding requires L-glutamate binding and thus they act as use-
dependent inhibitors.  DQP-1105 decreases open probability by increasing the mean shut time 
without affecting mean open time and has minimal effects on channel conductance.  Thus, the 
non-competitive inhibition appears to be through reducing the probability of channel 
activation and not by reducing the stability of the open state. 
3.2.3 GluN2C/D selective NAMs: The Iminothiazolidinone series and their SAR 
A novel series of NAMs showing a slight preference for GluN2C/D containing 
NMDARs was identified from a medium-throughput screen65. The lead compound, 20, 
consisted of an iminothiazolidinone ring attached to a thiophene via an acetamide linker 
(Figure 10a). Alterations to the substituents on the thiophene ring suggested that the ethyl 
group at R3 was favorable, with its removal (R3 = H) or replacement with methyl (R3 = Me) 
proving deleterious to activity (Figure 10b). The introduction of alkyl substituents at R2 (e.g. 
Me or Et) also proved detrimental. In contrast, the methyl ester could be replaced with an 
ethyl ester (R1 = Et) without adversely affecting potency. With shortening or removal of the 
ethyl group at R3 decreasing activity, the authors hypothesized that a hydrophobic pocket may 
exist at this position. To explore this theory, the thiophene was replaced with various bicyclic 
thiophene rings. Several of these analogues (e.g. 21, Figure 10c) proved quite potent in a 
TEVC assay, with the incorporation of heteroatoms (S or O) into the ring giving potent 
inhibitors with marginal selectivity for GluN2D over GluN2A. For example, 21 displayed an 
IC50 of 0.8 µM against both GluN2C and GluN2D compared to 6.2 µM and 12.2 µM for 
GluN2A and GluN2B, respectively.  
  
  
Figure 10: (a) Lead compound 20; (b) General SAR observations; (c) Compounds 21 and 22. 
Changes to the aminothiazolidinone ring, namely changing the heteroatoms, were not 
well tolerated. For example, replacement of the imine with a carbonyl (i.e. Y = O) or 
methylation of both nitrogen atoms (i.e. X = Y = NMe) led to all inhibitory activity being lost. 
This suggested that hydrogen bond donor groups were essential for NAM activity. Although 
none of the compounds were particularly selective, some did show submaximal inhibition at 
saturating concentrations. Thus, as proposed for some of the naphthoic acid based NMDAR 
NAMs (section 4.1.2)66, inhibitory activity may provide neuroprotection without risking 
  
excessive blockade. In addition, the neuroprotective effect of another potent compound, 22, 
was demonstrated in an assay using cultured hippocampal neurons challenged with NMDA. 
 
3.2.4 GluN2C/D selective NAMs: The N-aryl benzamide series and their SAR 
A screen of 100,000 compounds, which had already resulted in the discovery of a series 
of GluN2C selective PAMs (see section 5.3.1), identified N-aryl benzamide 23 as a novel 
NAM of GluN2C/2D containing NMDARs (Figure 11a)67. When tested on recombinant 
NMDARs in Xenopus oocytes, 23 displayed IC50s of 2.6µM and 1.4µM versus GluN2C and 
GluN2D respectively, with >400-fold selectivity for these subunits over GluN2A/B. 
However, despite promising activity, 23 had poor aqueous solubility so an SAR optimization 
study was carried out. 
48 analogues of 23 were synthesized and tested leading to a number of general SAR 
observations, the most important of which are summarized in Figure 11b. Replacing the 
carbamothioate in 23 with a carbamate improved aqueous solubility but decreased both 
activity and selectivity. However, replacement of the naphthalene with an indole ring restored 
low micromolar potency whilst retaining improved solubility. Shortening or extending the 
alkyl component of the carbamate to either N,N-dimethyl or N,N-diisopropyl was found to 
reduce potency. A variety of substituents were introduced to the indole ring, but all were found 
to reduce activity or abolish it completely. Overall, NAB-14 (24) displayed the best 
combination of activity, selectivity and aqueous solubility (Figure 11c). 
 
  
 
Figure 11: (a) Lead compound 23; (b) General SAR observations; (c) Compound 24 (NAB-
14). 
 
4. NMDAR modulator families with NAM and PAM activity with varying 
selectivity 
4.1 Phenanthrene, Naphthalene and Coumarin Carboxylic Acids  
4.1.1 The phenanthrene series and their SAR  
The phenanthrene series of PAMs and NAMs were identified through a small in-house 
compound screen on NMDARs68. These compounds displayed several distinct, novel patterns 
  
of activity with NAM and/or PAM activity and varied subtype-selectivity. The lead 
compound, 9-iodophenanthrene-3-carboxylic acid, 25 (UBP512) (Figure 12a) was found to 
potentiate GluN2A, have virtually no activity at GluN2B, and inhibit GluN2C/D responses 
(IC50 ~ 50 µM). UBP512 potentiation of GluN1/GluN2A responses increased with higher 
agonist concentrations, showing that the mechanism of potentiation is not by increasing 
agonist potency.  A series of analogues were subsequently synthesized to try and exploit this 
selectivity whilst improving the activity. A SAR study was carried out investigating 
substitutions at the 9-position and modifications to the acidic group at the 3-position (Figure 
12b).  
Alkyl substituents at the 9-position appeared to promote potentiating activity; increasing 
the length or size of the alkyl chain increased NMDAR PAM activity. Introduction of a polar 
group into the side chain, however, promoted antagonism. Inserting a CH2 linker between the 
ring and carboxylic acid also promoted antagonism rather than potentiation69. Some of these 
compounds also had mixed subunit selectivity; UBP710 (26), with a cyclopropyl group at the 
9-position, potentiated GluN2A/B and weakly inhibited GluN2C/D-containing receptors at 
higher concentrations68. UBP646 (27), with a large hydrophobic iso-hexyl group, was found 
to be a pan potentiator (Figure 12c).  
 
  
 
Figure 12: (a) Lead compound 25; (b) General SAR observations; (c) 26 (UBP710), 27 
(UBP646). 
4.1.2 Naphthoic acid series and their SAR 
In a follow up study to the phenanthrene-based research, compounds with a naphthoic 
acid core were synthesized to probe the importance of the three rings to activity (Figure 13a). 
Although many of the compounds in this series displayed NAM activity, the addition of a 
long chain alkyl group at R4 led to potentiation. As found for the phenanthrenes, extending 
the alkyl side-chain from propyl to hexyl progressively increased PAM activity. One of the 
most effective pan PAMs in the series, UBP684 (28), had an i-hexyl substituent at the R4 
position (Figure 13b)70.  In the absence of an alkyl side-chain, the naphthoic acid derivatives 
were predominately non-selective NAMs whose potency across the GluN2 subunits was 
increased by halogen substituents at R2 and R5, a hydroxy group at R1, and a phenyl ring at 
  
R5 in a generally additive manner (Figure 13a). Thus, increasing potency reduced selectivity 
such that 1-bromo-2-hydroxy-6-phenyl-3-naphthoic acid, 29 (UBP618), is a non-selective 
NAM with an IC50 ~2 µM
66. The carboxylic acid was found to be crucial to activity; removing 
it from one of the more potent analogues eliminated activity. Phenyl substituents at R5 
afforded NAMs that cannot maximally inhibit NMDARs (maximal inhibition of 60 – 90%), 
thus potentially generating antagonists that might not excessively inhibit function (Figure 
13a)68.  
The 3,5-dihydroxy derivative of 2-naphthoic acid, UBP551 (30), showed PAM activity 
on GluN2D but NAM activity on GluN2A-C and is therefore a lead for the development of 
GluN2D selective PAMs (Figure 13b)68. 
 
  
Figure 13: (a) General SAR observations; (c) Representative naphthalene derivatives from 
the series: 28 (UBP684), 29 (UBP618), 30 (UBP551) and 31 (UBP552). 
4.1.2.1 Naphthoic acid series PAMs: UBP684 mechanism of action 
The naphthoic acid derivative UBP684, 6-(4-methylpent-1-yl)-2-naphthoic acid (28),  
displays robust potentiation of each of the four GluN1/GluN2 receptors and was thus selected 
for further mechanistic studies70, 71. UBP684 increases open probability in a use-independent 
manner in the presence of saturating concentrations of agonist70. Potentiation is associated 
with a minor increase in L-glutamate potency at GluN2A and a decrease in L-glutamate 
potency at GluN2C and GluN2D. Despite these opposite actions of UPB684 on L-glutamate 
potency at GluN2A and GluN2D, UBP684 potentiates the steady-state response, and slows 
the deactivation upon L-glutamate removal, at both of these receptors70. The potentiation of 
steady-state responses appears to be distinct from the slowing of deactivation; the potentiation 
response is lost in dialyzed cells from whole-cell recordings, whereas the slowed deactivation 
remains71. Thus, like PAM activity of PS, the intracellular environment can differentially 
affect the potentiation mechanisms of UBP684. 
Channel analysis71 indicates that potentiation by UBP684 is due to an increase in open 
probability by increasing mean open time and reducing the long-lived shut times with no 
change in the single channel conductance. PAM activity appears to specifically affect gating 
steps governed by the GluN2 subunit’s LBD, a result that is consistent with the finding that 
steady-state PAM activity requires a conformational change in the GluN2 LBD, but not that 
of GluN1’s LBD70, 71.  Studies of pH effects on PAM activity revealed that the PAM activity 
of UBP684, PS, CIQ, and GNE-8324 were all reduced at high pH, with UBP684 and GNE-
8324 even becoming NAMs at pH 8.470.  This suggests the possibility that these PAMs 
stabilize a receptor conformation that is intermediate between the fully-protonated, inhibited 
  
receptor and the de-protonated, maximally responsive receptor. 
 
4.1.2.2 Naphthoic / phenanthroic acid series PAM binding site(s)  
 The binding site for the naphthoic / phenanthroic acid series of PAMs is not known 
but appears to be either at the LBD dimer interface or closer to the TMD.  Removal of both 
the GluN1 and GluN2 ATDs does not eliminate the potentiating activity of UBP51268.  These 
agents also do not compete with L-glutamate or glycine and cannot mimic either agonist; thus, 
they are not binding in the ligand-binding cleft of the LBD of GluN1 and GluN2.  They also 
do not have voltage-dependent activity and do not compete with ketamine for the channel 
binding site, thus they do not appear to bind in the central pore of the channel. In 
GluN2A/GluN2C chimeras, UBP512 PAM activity is associated with S2.  Thus, the PAM 
binding site may overlap with the PS PAM binding site that involves S2 and M4 and/or the 
LBD dimer interface site that involves S1 and S2.  Residues in M4 are critical for 
UBP512/UBP684 PAM activity (Figure 8), hence M4 may be contributing to PAM binding 
or the transduction of PAM activity.   
4.1.3 Coumarin-3-carboxylic acid series NAMs / PAMs and their SAR 
The previously described SAR studies on 2-naphthoic acid derivatives led to the 
identification of a structurally related coumarin (32, UBP608, Figure 14a) which displayed 
NAM activity with weak selectivity toward GluN2A containing NMDARs (IC50 = 19, 90, 68, 
and 426 µM at GluN2A-D, respectively)66. With respect to SAR, the 6-bromo group was 
found to be important with its removal proving detrimental to activity (Figure 14b)72. Whilst 
the 6-bromo substituent could be replaced with an iodo to afford a derivative with similar 
activity and selectivity, the introduction of a more polar 2-carboxyvinyl moiety (33, UBP656) 
significantly reduced potency across all 4 subtypes (Figure 14c). The introduction of a bromo 
  
group at the 8-position enhanced activity but led to reduced GluN2A selectivity. Interestingly, 
4-methyl substitution of UBP608, yielding 34 (UBP714), turned the compound from a NAM 
to a weak PAM (Figure 14c). UBP714 displayed low levels of potentiation at GluN2A, 
GluN2B and GluN2D, respectively73. UBP714 also enhanced NMDAR EPSPs evoked in 
hippocampal slices. 
 
4.1.4 Coumarin 3-carboxylic acid / naphthoic / phenanthroic NAM binding site(s) and 
mechanisms of action. 
NAM activity of the naphthoic acid and phenanthroic acid derivatives is voltage-
independent, and use-independent66, 68.  The IC50 of UBP552 (31, Figure 13) is increased only 
3-fold in the presence of 150-fold higher L-glutamate concentration and 30-fold higher 
glycine concentration, thus the NAM activity is non-competitive and unlike TCN-201 which 
behaves largely as a competitive glycine antagonist. Channel analysis indicates that 2-
naphthoic acid decreases mean open time and increases mean closed time74. This action 
appears to be due to stabilizing closed states and making it more difficult to open the channel.  
The NAM binding site is unknown, but NAM activity remains after removal of the ATD of 
both GluN1 and GluN268.  These agents also cannot substitute for, or compete with, either L-
glutamate or glycine, so they do not appear to bind within the LBD cleft. GluN2A/2C 
selectivity of UBP618 requires residues in the S1 domain. 
 
 
  
  
Figure 14: (a) Lead compound 32 (UBP608); (b) General SAR observations; (c) 
Representative coumarin derivatives from the series: 33 (UBP656) and 34 (UBP714). 
5. Non-steroidal NMDAR PAMs 
5.1 Non-selective PAMs  
5.1.1 Benzenesulfonamide 
The non-selective PAM GNE-9278 (35), which potentiates each of the GluN1/GluN2 
NMDARs in the low micromolar range, was recently reported by Wang and colleagues 
(Figure 15)75. This compound potentiates by increasing the potency of both L-glutamate and 
glycine and by increasing the peak response in the presence of saturating concentrations of 
agonists.  At higher concentrations, GNE-9278 slows deactivation upon L-glutamate removal.  
Consistent with a strong allosteric interaction between the agonist binding site and the PAM 
binding site, GNE-9278 binding is thought to be dependent upon agonist binding. The effect 
on channel properties is unknown.  The structural determinants for activity of this compound 
include residues T550 and D552 in the GluN1 pre-M1 helix at a site near to where residues 
  
on GluN2C/D are important for CIQ activity (Figure 8).  Binding at this site can then influence 
gating at the nearby extracellular end of M3. 
  
Figure 15: Structure of GNE-9278 (35). 
5.2. GluN2A selective PAMS 
5.2.1 Thiazole series 
Recent studies have now provided selective GluN2A PAMs with reasonable potency 
and drug-like properties.  These agents bind at the same GluN1/GluN2 LBD dimer interface 
as the TCN-201 family of NAMS59, 76.  The research involved hit identification via high-
throughput screening for GluN2A PAM activity, followed by lead optimization using a 
combination of X-ray crystallography, structure-based design and SAR studies. The lead 
compound, designated GNE-3476 (36)76, displayed low micromolar potency at GluN2A, 
some activity as an AMPAR PAM, and weak activity at GluN2B-containing receptors (Figure 
16a). Further studies confirmed that the compound was acting as an allosteric modulator and 
identified several structurally-related compounds that display 10-fold to 100-fold selectivity 
for GluN2A over GluN2B and still greater selectivity over GluN2C/D containing NMDARs59.  
5.2.1.1 Thiazole series GluN2A PAM SAR 
Compounds were tested for their ability to potentiate either NMDARs or AMPARs 
using a calcium imaging assay and evaluated for their P-glycoprotein efflux ratio (P-gp ER) 
  
to identify favorable CNS properties. Initial attempts to optimize the GluN2A PAM activity 
indicated that shortening the butyl chain and adding a fluoro group at the para- position of 
the aniline ring enhanced PAM activity at GluN2A. A crystal structure of one of these 
optimized analogues bound to the receptor was obtained and showed the binding site to be 
located at the dimer interface of the GluN1-GluN2A LBD76. This turned out to be the same 
site where PAM binding is observed in AMPARs77, explaining the poor selectivity over 
AMPARs for the initial lead. This binding site also has significant overlap with the TCN-201 
NAM binding site discussed above. Thus, ligands at this site can either be NAMs or PAMs 
depending upon the specific interactions within the binding pocket. 
The pharmacokinetic properties of these lead compounds were generally favorable for 
use in the CNS; moderate log D (<3) and low topographical polar surface area (<90 Å2) values 
were recorded, however, poor metabolic stability was observed, in particular as a result of N-
dealkylation. Consequently, one aim of the optimization study was to replace the N-ethyl 
aniline with a more metabolically stable group (Figure 16b). Although various aryl and 
heteroaryl moieties were explored, a 3-trifluoromethyl pyrazole was identified as a good 
candidate. Modelling studies suggested that substituents at the 5-position of this heterocycle 
could occupy the same binding pocket as the N-ethyl group in the lead compounds. Various 
groups were subsequently investigated with a 5-chloro moiety proving optimal for GluN2A 
activity and selectivity. 
Another aim of the study was to explore a water-filled pocket proximal to the 
thiadiazole-core nitrogen which had been identified from the crystal structure. While 
AMPARs have a similar pocket in their equivalent site it is relatively small, meaning a large 
group could potentially enhance selectivity for NMDARs over AMPARs. To investigate this, 
the thiadiazole core was replaced with a thiazole thereby allowing substituents to be 
  
introduced to the 3-position of the ring (Figure 16b). This change was found to moderately 
improve GluN2A PAM activity on its own. The introduction of polar  
   
Figure 16: (a) Lead compound GNE 3476 (36); (b) Summary of SAR study; (c) Structures of 
GNE-0723 (37), GNE-5729 (38), GNE-6901 (39) and GNE-8324 (40). 
  
groups to the 3-position generally improved GluN2A activity and selectivity but increased the 
P-gp ER, making the resultant analogues less effective at crossing the blood brain barrier 
(BBB). Achieving a balance between activity, selectivity, metabolic stability and ability to 
cross the BBB proved challenging. However, by utilizing a cyclopropyl nitrile substituent at 
the 3-position of the thiazole ring a balance was eventually achieved. Lastly, the addition of 
a trifluoromethyl group to the 2-position of the thiazole core improved selectivity over 
AMPARs and afforded GNE-0723 (37), the most successful compound in the series (Figure 
16c). The large hydrophobic group is believed to be incompatible with the polar serine and 
asparagine residues in the equivalent site of the AMPAR, explaining the 250-fold selectivity 
for GluN2A over AMPARs. This selectivity was achieved without compromising potency 
(EC50 = 0.021 μM) or metabolic stability. 
A crystal structure of GNE-0723 bound to GluN2A59 showed, as predicted, that the 
conformation of the trans-cyclopropyl enables the nitrile moiety to occupy the water-filled 
pocket. Selectivity over GluN2B/C/D was also achieved; GNE-0723 was ~300-fold more 
selective for GluN2A over GluN2C and GluN2D and yet more selective over GluN2B with 
weak potentiation at 100 µM. A later optimization campaign, using GNE-0723 as a lead 
compound, saw a pyridopyrimidinone replace the previous thiazolopyrimidinone core. This 
led to GNE-5729 (38), which displayed an improved in vivo pharmacokinetic profile (Figure 
16c)78.  
 
5.2.1.2 Thiazole series GluN2A PAM binding site and mechanism of action 
Precisely how GNE-6901/GNE-0723 (39/37, Figure 16c) potentiate GluN1/GluN2A 
receptor responses is not known, but they appear to stabilize the agonist-bound conformation. 
These compounds increase agonist efficacy and have variable effects on agonist potency59. 
  
Crystallographic studies indicate that, like TCN-201, GNE-6901 selectivity for GluN2A is 
due to V783. Replacing this residue in GluN2A with the corresponding residue from GluN2B 
(phenylalanine) essentially eliminates GNE-6901 PAM activity and substituting valine for 
this residue in GluN2B enables PAM activity (but of several-fold lower potency than 
GluN2A)59.  A potentiation mechanism is suggested by the observation that AMPAR 
potentiators that bind at this site have been shown to reduce desensitization and slow 
deactivation by stabilizing the AMPAR LBD dimer interface and the agonist-bound LBD in 
its closed cleft conformation77. Consistent with this mechanism, binding of GNE-8324 (40, 
Figure 16c) to GluN1/GluN2A causes a marked slowing of deactivation associated with L-
glutamate removal but not with glycine removal.  Interestingly, however, the closely related 
compound GNE-6901 only causes a modest slowing of deactivation following L-glutamate 
removal59.  GNE-8324 also causes a greater increase in L-glutamate potency than does GNE-
6901, and reciprocally, increasing concentrations of L-glutamate increases GNE-8324 
potency but minimally increases GNE-6901 potency.  Thus, GNE-8324 PAM activity is 
consistent with a stabilization of the closed, L-glutamate bound GluN2A LBD conformation, 
but PAM activity of GNE-6901 appears to require an additional mechanism for increasing 
agonist responses.   
In contrast to the NAM activity of TCN-201, the PAM activity of GNE-6901 is not 
associated with a displacement of the side chains of GluN2A’s V783 and, instead, is 
associated with a movement of GluN1 Y535 and GluN2A E530 side chains59.  The GluN1 
Y535 residue interacts with the GluN2 hinge region and mutating this residue affects 
deactivation upon L-glutamate removal and open channel probability.  Thus, GNE-6901 
potentiation may involve this residue51 although this could not be confirmed by mutational 
  
analysis59.  Presently, single channel studies of GNE compound activity have not been 
reported, but such studies should help reveal the mechanism of action. 
5.3. GluN2C selective PAMs 
 5.3.1 The pyrrolidinone series  
The first GluN2C-selective PAM was obtained from a series of pyrrolidinones79, 80. The 
most active analogues of these allosteric potentiators were over 100-fold selective for 
receptors containing GluN2C over GluN2A, B and D. The lead compound – identified 
through library screening/bioinformatics searches – was pyrrolidinone 41 (Figure 17a).  
5.3.1.1 The pyrrolidinone series: SAR 
To gather SAR information and optimize PAM activity on GluN2C, a large number of 
structural analogues of 41 were synthesized and tested (Figure 17b). Interestingly, these 
modifications revealed a relatively flat SAR indicating that most of the structure was already 
optimized. For example, PAM activity was either lowered or abolished completely by: (i) 
changing the position or type of substituents on ring A, (ii) replacing ring B with various aryl 
or heteroaryl systems, (iii) modifying the enol or (iv) shortening or lengthening the alkyl 
linker (Figure 17b). However, changes to R1 indicated that there was room for larger 
substituents at this position with either a phenyl, 3-pyridyl or 4-pyridyl ring bestowing 
moderately better activity (interestingly the 2-pyridyl derivative was inactive). Changing the 
methyl ester on ring A to an ethyl ester was tolerated, but bulkier esters proved detrimental. 
The space surrounding ring B was systematically explored by the addition of various 
substituents (e.g. R3 = F, Cl, Me, OMe). This identified the 6-position as being optimal with 
a methyl group giving the best activity. Finally, methylation of the indole nitrogen abolished 
activity thus suggesting a hydrogen bond donor role for the  
  
  
Figure 17: (a) Lead compound 41; (b) General structure for SAR studies; (c) Compounds 42 
(PYD-111) and 43 (PYD-106). 
  
indole hydrogen (Figure 17b). Combining these observations gave compound 42 (PYD-111), 
which was the most potent of the series, selectively potentiating GluN2C-containing receptors 
up to 219% with an EC50 of 4.3 ± 0.3 µM. On separation of the enantiomers for a 
representative analogue from the series, it was found that the activity of the compounds 
originates solely from one enantiomer. Although relatively few alterations were made to the 
original molecule the activity was significantly enhanced. 
 
5.3.1.2 The pyrrolidinone series: PYD-106 binding site and mechanism of action 
The mechanism of action of an analogue from the series, PYD-106 (43, Figure 17c), has 
been proposed. PYD-106 potentiation of GluN1/GluN2C NMDAR responses appears to be 
predominately through increasing agonist efficacy rather than a change in agonist potency79.  
Thus, under saturating agonist concentrations, PYD-106 can increase the maximal receptor 
response.  There is, however, some effect on agonist potency; PYD-106 causes a small 
increase in glycine potency and a small reduction in L-glutamate potency.  Single channel 
analysis indicates that PYD-106 does not change channel conductance, and instead potentiates 
GluN1/GluN2C receptor responses by increasing mean open time and may also increase 
opening frequency.  Thus, PYD-106 stabilizes an open channel state of the receptor complex. 
The activity of PYD-106 is notable because it is unusual to identify compounds that can 
distinguish GluN2C from GluN2D.  This suggests that PYD-106 binds to site with greater 
GluN2 sequence variability.  By using a series of GluN2A/GluN2C chimeras, the ATD, S1 
and the ATD-S1 linker were identified as being important for PYD-106 activity79.  
Subsequent evaluation of an extensive panel of point mutations then lead to the proposal of a 
binding pocket between the ATD and S1 that could accommodate PYD-106 (Figure 18).  
  
Further point mutations based on the docking in a homology model provided additional 
support for this GluN2 ATD/S1 binding pocket being the PYD-106 binding site.  This binding 
site is likely to influence communication between the ATD and the LBD and thus appears to 
represent a novel mechanism of NMDAR potentiation. Structural studies are needed to 
confirm the PYD-106 binding site and to determine how binding influences receptor 
conformation. 
5.3.2. GluN2C/D PAMs: The tetrahydroisoquinoline series (CIQ) 
A series of tetrahydroisoquinoline derivatives has been reported as selective potentiators 
of GluN2C and GluN2D containing NMDARs81. The lead compound for this series was CIQ 
(44, Figure 19a), which displayed an EC50 of 3 µM and enhanced receptor responses ~2-
fold82. To gather SAR information and improve activity, a number of structural analogues of 
CIQ were synthesized and tested. Evaluation of the ability of these compounds to potentiate 
GluN2 subunits was carried out using both calcium imaging assays and TEVC recordings. 
5.3.2.1 GluN2C/D PAMs: The tetrahydroisoquinoline series: SAR 
The main skeleton of the structure was found to be essential with removal of ring B and 
the ether linker abolishing activity (Figure 19b)81. Shortening the linker to a single methylene 
carbon or replacing it with either a thioether or ethyl linker led to a similar outcome. Altering 
the position and substituents on ring B established that a p-OMe group was optimal for PAM 
activity. Replacing ring A with a variety of aromatic and heteroaromatic systems was 
detrimental, although a 2-thiophene replacement showed some potential as a starting point for 
gaining selectivity for GluN2C- over GluN2D-containing NMDARs. The amide between ring 
A and the tetrahydroisoquinoline core was also important with its replacement with various 
other linkers (e.g. urea or sulfonamide) either  
  
  
Figure 19: (a) Lead compound 44 (CIQ); (b) General SAR observations; (c) Compound 45. 
reducing activity or abolishing it completely. Altering the position and substituents on ring A 
showed that meta- substitution gave the strongest potentiation and, of those tested, halogen 
substituents gave the best activity. With respect to ring C, introducing substituents to the 3-
  
position reduced PAM activity, potentially due to an undesirable steric clash with the nearby 
ether linker. Additionally, substituents at the 6-position abolished activity suggesting a steric 
restriction around this area of the binding site. Interestingly, 5-OMe derivatives were found 
to be more active than their 4,5-diOMe counterparts. The most potent compound of the series, 
45 (EC50 = 0.3 µM at GluN2C and GluN2D), was obtained by placing an O-benzyl group at 
the 5-position of ring C, thereby suggesting a hydrophobic pocket exists at this area of the 
binding site (Figure 19c). As all the compounds were tested as racemic mixtures for ease of 
synthesis, it was suspected that only one enantiomer may be responsible for the potentiating 
effect. Stereoselective synthesis and testing of the enantiomers of CIQ (44) revealed that the 
potentiating activity arises from a single enantiomer, namely (+)-CIQ (the absolute 
stereochemistry of this enantiomer has yet to be confirmed)83. 
Further structural modification of the tetrahydroisoquinoline backbone led to the 
development of compounds, which displayed PAM activity at GluN2B as well as GluN2C 
and GluN2D containing NMDARs84. Removing the 4-OMe group from ring C of CIQ and 
replacing the 5-OMe with a branched isopropyl ether afforded a PAM (46) which had activity 
at GluN2B/C/D subunits (Figure 20a). SAR studies on 46 established that various other 
branched or cycloalkyl ethers (e.g. R1 = i-Bu, cHex) were tolerated at the 5-position of ring 
C (Figure 20b). Furthermore, it was found that PAM activity could be increased significantly 
by changing the linker between ring A and the tetrahydroisoquinoline core from amide to 
thioamide (i.e. X = S). Enantiomeric separation revealed that the S-(-) enantiomer of 46 was 
active at GluN2B/C/D while the R-(+) enantiomer was only active at GluN2C/D. S-(-)-46 was 
one of the most active PAMs to be developed with EC50’s of 0.32, 0.48, and 0.48µM at 
GluN2B/C/D subunits respectively. Additionally, this series of compounds displayed 
selectivity for NMDARs over AMPA and kainate receptors (Figure 20). 
  
  
Figure 20: (a) Lead GluN2B/C/D PAM 46; (b) General SAR observations; (c) Active 
enantiomer of 46. 
5.3.2.2 GluN2C/D PAMs: The tetrahydroisoquinoline series; CIQ binding site and 
mechanism of action 
The potentiation action of CIQ on GluN1/GluN2D involves residues in the linker 
between the GluN2D ATD and S1, and GluN2D specificity involves Thr592 in M182 (see 
Figure 8). Further chimera and point mutation analysis suggests the involvement of the ATD 
linker may be to facilitate potentiation but that residues immediately preceding M1 (pre-M1 
cuff helix which lies parallel to the membrane) and several residues within M1, are 
specifically necessary for CIQ actions85.  This putative binding site location is thus well 
positioned to affect gating by modulating the interactions between pre-M1/M1 and M3. 
  
The mechanism of potentiation by CIQ is distinct from that found for UBP684 and 
GNE-6901(see sections 4.1.2.1 and 5.2.1.2).  CIQ increases open probability, but does not 
increase the mean open time82.   Instead, CIQ decreases mean shut time.  Thus, CIQ appears 
to enhance a pre-gating step by lowering the energy barrier for channel opening but does not 
appear to stabilize the open state.  These results are consistent with a minimal effect on agonist 
potency and receptor deactivation time.  CIQ appears to bind either in the absence or presence 
of agonist. 
6. Conclusion 
In recent years, significant progress has been made in the development of selective 
allosteric modulators binding to newly-identified sites on NMDARs. These new binding sites 
have already shown great potential as targets for both therapy and tool development; the 
apparent presence of a diverse range of binding pockets has meant that selective ligands for 
several of the subtypes have been identified, with both potentiating and inhibiting activity. 
There are now NAMs selective for GluN2A, GluN2B and GluN2C/D and PAMs selective for 
GluN2A, GluN2C, and GluN2D. Although there are a number of compounds that are of 
adequate potency for pharmacological characterization and potential starting points for 
therapeutic investigations, there is still a need for new compound development. Future studies 
should focus on 1) increasing the structural diversity of lead compounds, 2) improving 
pharmacodynamic properties and optimizing the balance between water solubility and 
lipophilicity (this has been challenging in some of the SAR studies described herein) in order 
to improve bioavailability, 3) improving selectivity for individual GluN2 subunits, 4) 
developing compounds that are selective for triheteromeric NMDARs (i.e. those containing 
two GluN1 and two different GluN2 subunits), and 5) developing related agents to distinguish 
NMDARs containing GluN3 subunits. The finding that PYD106 is ineffective on 
  
heterotrimeric GluN2C-containing NMDARs79, suggests that it may be possible to develop 
other agents that can further distinguish triheteromeric from diheteromeric receptors.  
These endeavors would be aided by structural information obtained from protein-ligand 
complexes. For agents that bind in the LBD interface, recent crystallography studies have 
characterized the binding sites in detail.  Other agents that bind near or in the membrane or 
between the ATD and LBD await such detailed structural information, but recent AMPAR 
structures with homologous binding sites can already provide some insights86. As we 
determine the exact mechanisms of action and establish the structures of the binding pockets, 
it should become possible to tap into the potential of these new NMDAR binding sites even 
further, with compounds of increased potency and selectivity.  
The new classes of drugs represented by these varied NMDAR NAMs and PAMs should 
offer significantly greater pharmacological control over NMDAR modulation than the 
previously available competitive antagonists and channel blockers. In addition to the 
improved targeting of specific subtypes, these agents have a surprising diversity in 
physiological properties at the receptor level that lead to distinct effects at the level of synaptic 
transmission and neuronal network function. These varied properties mean that it is possible 
to pharmacologically target distinct NMDAR populations in specific 
physiological/pathological conditions. These agents differ in their pH-sensitivity, thus can 
have a differential effect under pathological acidosis.  The differ in their use/disuse-
dependency and hence they can preferentially affect responses due to phasic or tonic agonist 
exposure. These agents can also differ in their effects on agonist potency, agonist efficacy and 
agonist deactivation kinetics. Reciprocally, some NAMs/PAMs differ in how their 
modulatory activity is affected by high and low agonist concentrations.  Thus, an agent can 
potentially target pathological conditions that are excitotoxic due to chronic, low 
  
concentrations of extracellular glutamate, but minimally affect the phasic, high concentration 
glutamate exposure seen in synaptic transmission. With evidence that phosphorylation state 
and other intracellular factors can alter modulator activity, it may be possible to develop 
agents that target receptors on cells with specific intracellular conditions. Furthermore, 
modulators that slow NMDAR deactivation time could specifically enhance the response to 
repetitive synaptic activity that occurs during burst neuronal firing.  
To date, medicinal chemistry has focused on compounds with improved selectivity and 
potency.  Present efforts are to improve solubility, brain penetration, and 
pharmacokinetic/toxicity properties. But a remaining challenge will be to understand the 
structure-function properties of these allosteric modulators that underlie their diverse and 
specific physiological properties, thus enabling targeted drug design for optimal activity. 
Overall, there is significant potential to develop NMDAR NAMs and PAMs with improved 
properties for a variety of indications such as pain, epilepsy, neuroprotection, cognitive 
enhancement, and conditions of NMDAR hypofunction such as schizophrenia.  
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ATD, amino terminal domain 
BBB, blood brain barrier 
EPSP, excitatory postsynaptic potential 
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GluN1,2,3, Glutamate receptor subunit, NMDA type 1-3 
KAR, kainate receptor 
LBD, ligand-binding domain 
M1-M4, membrane-associated domain 1-4 
NAM, negative allosteric modulator 
NMDA, N-methyl-D-aspartate 
NMDAR, N-methyl-D-aspartate receptor 
PAM, positive allosteric modulator 
PAS, pregnanolone sulfate or 20-oxo-5β-pregnan-3-yl sulfate 
P-gp ER, P-glycoprotein efflux ratio 
PS, pregnenolone sulfate or 20-oxo-5-pregnen-3β-yl sulfate 
S1 segment 1 
S2 segment 2 
SAR, structure activity relationship 
TEVC, two-electrode voltage clamp 
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Color Figure Legends 
Figure 1 
NMDA receptor structure. (Top) Crystal structure of the tetrameric NMDA receptor 
complex of Xenopus laevis without intracellular C-terminals 87 (PDB: 4TLM).  The two 
GluN1 backbones are shown in green/blue and the two GluN2B backbones are in yellow/red. 
(Bottom row) A single GluN1 subunit in the same orientation as the blue GluN1 subunit in 
the top, left panel.  Middle panel showing this subunit’s secondary structure (beta sheets, blue 
/ alpha helix, red) and right panel: stick representation of backbone and side chains with the 
ATD - green, S1and linker to M1- red, S2 and linker to M4 - blue, M1 – yellow, M2 - orange, 
M3 - magenta, and M4 - cyan. The three domain levels are shown on the left for ATD, LBD, 
and transmembrane (TM) domain. 
Figure 5 
Allosteric modulator binding sites on the NMDA receptor. (Left panel) Crystal structure 
of the tetrameric NMDA receptor complex of Xenopus laevis without intracellular C-
terminals 87 (PDB: 4TLM).  The two GluN1 backbones are shown in green/blue and the two 
GluN2B backbones are in yellow/red.  Homologous amino acid residues which are involved 
in the binding and/or actions of allosteric modulators are shown as space-filled: PYD-1 – light 
blue; GNE-6901/TCN-201 - yellow; UBP512 - pink; QNZ46/DQP-1105 - orange; GNE-9278 
- green; CIQ - purple. Also shown are space-filled ligands with CPK coloring: Ro25-6981 
bound in the ATD, glycine-site agonist 1-aminocyclopropanecarboxylic acid bound in the 
GluN1 LBD, and glutamate-site agonist trans-1-aminocyclobutane-1,3-dicarboxylic acid 
bound in the GluN2B LBD.  (Right) LBD dimer with homologous residues that interact with 
TCN-201 are shown as space-filled in blue (GluN1) and yellow (GluN2).  Bound glycine and 
L-glutamate are shown in CPK coloring. 
  
Figure 6 
(A,B) GluN1/GluN2A LBD dimer with bound TCN-201 (yellow), L-glutamate (green), 
and glycine (light blue) PDB: 5I56 51. (C) TCN-201 binding pocket with interacting residues 
shown in stick mode. 
Figure 8 
Allosteric sites associated in or near the TM domain. The two GluN1 backbones are 
shown in green/blue and the two GluN2B backbones are in yellow/red.  Homologous amino 
acid residues which are involved in the binding and/or actions of allosteric modulators are 
shown as space-filled: UBP512 - pink; QNZ46/DQP-1105 - orange; GNE-9278 - green; CIQ 
- purple. UBP512 and PS activity also involves residues in the S2 domain (not shown). 
Figure 18  
Residues important for PYD-106 GluN1/GluN2C-selective PAM activity.  (Left) 
Residues important for NAM/PAM activity are shown in the tetrameric complex with GluN1 
backbones in blue/green and GluN2 backbones in red/yellow (PDB: 4TLM).  Residues 
homologous to those important for PYD-106 GluN2C-selectivity are shown on a single 
GluN2 structure as space-filled in light blue.  These sites oppose each other across the 
ATD/LBD interface. 
 
 
 
 
 
  
Table 1: Functional characteristics of NMDA receptor allosteric modulators 
 
PO, open probability; MOT, mean open time; MST, mean shut time.  b* NAM at neutral pH 
- not available,  
 
PAM or NAMb Effect on agonist potency Deactivation  Use dependency Single-channel properties             pH Ref 
Glutamate Glycine                PO          MOT          MST  Low High  
GNE-6901 (GluN2A) No change No change No change - - - - - - [59] 
GNE-8324 (GluN2A) ↑ No change Slow (Glu) - - - - PAM NAM [59,70]  
GNE-9278 (GluN2A) ↑ ↑ Slowed (Glu) Use-dependent?      [75] 
UBP684 (GluN2A) ↑ No change Slowed Use-independent ↑ ↑ ↓ PAM NAM  [70,71] 
UBP684 (GluN2D) ↓ No change Slowed (Glu) Use-independent - - - PAM NAM [70] 
UBP753 (GluN2D) ↓ No change No change  Use-independent - - - PAM NAM [70] 
PYD-106 (GluN2C) ↓ ↑ Faster (Glu) - ↑ ↑ No change - - [79] 
CIQ (GluN2D) No change Small ↑ No change Use-independent ↑ No change ↓  - [82,85] 
PS (GluN2A) No change No change Slowed  ↑ ↑ No change ↑ PAM ↓ PAM [24,33,45,29] 
PS (GluN2B) Small ↑ Small ↑ Slowed Dis-use dependent ↑   ↑ PAM ↓ PAM [44,28,24,70] 
Spermine (GluN2B)  ↑ Slowed (Gly) -    ↑ PAM ↓ PAM [88, 89] 
SGE-201 (GluN2A) ↑ No change - - ↑ - - - - [49] 
*PAS (GluN2A) ↓ ↓ - Use-dependent ↓ No change ↑ - - [24,41] 
*DQP-1105 
(GluN2D) 
- - - Use-dependent ↓ No change ↑ - - [63] 
*QNZ-46 (GluN2D) - - Slowed Use-dependent - - - - - [62] 
  
Table 2: Potency of negative allosteric modulators at different GluN1/GluN2 NMDAR  
NAMs IC50 (µM) Ref 
GluN2A GluN2B GluN2C GluN2D 
TCN-201c 0.11a 
0.446a 
0.32a  
034a,b 
50 
 
>>10 
- 
- 
>>10 
- 
>>30 
- 
>>10 
- 
[50] 
[52] 
[53,58] 
MPX-004 0.198/0.079b - - - [58] 
MPX-007 0.143/0.027a,b - - - [58] 
Ifenprodilb 39.5 0.11 29.1 75.9 [90] 
Ro 25-6981 52 0.009 - - [91] 
EVT-101 - 0.012 - - [92] 
QNZ-46 229 
182  
˃300 
193 
6 
7.1 
3 
3.9 
[60] 
[62] 
DQP-1105 - 113 7.0 2.7 [63] 
PAS 62 38 12 14 [24] 
UBP608 18.6 90 68 426 [68] 
UBP618 1.8 2.4 2.0 2.4 [68] 
UBP551 9.7 9.4 15 10 (PAM) [68] 
IC50 values were determined by TEVC using Xenopus oocytes 
- data not available 
a3 µM glycine was used for IC50 determination 
bIC50 was calculated at human NMDA receptors 
cAs determined by Ca2+ influx assay using HEK cells  
 
 
 
  
  
Table 3: Potency of positive allosteric modulators at different GluN1/GluN2 NMDAR 
PAMs EC50 (µM) Ref 
GluN2A GluN2B GluN2C GluN2D  
GNE-6901 8.5    [59] 
GNE-8324 2.43a - - - [59] 
GNE-9278 3.2 15.7 6.6 6.7 [75] 
Spermine - 127 
81c 
125d 
- - [89] 
[93] 
[88] 
PS 
 
21  
34b 
33  
63b 
112/NAM  
83b 
118 /NAM 
78b 
[24] 
[27b] 
CIQ 
PYD-106 
UBP512 
UBP684 
˃10 
N.A. 
~100 
28 
˃10 
N.A. 
N.A. 
34 
2.7 
13 
NAM 
37 
2.8 
N.A. 
NAM 
29  
[82] 
[79] 
[68] 
[70] 
R-(+)-138 
S-( ̶ )-138 
- 
- 
- 
0.32 
1.7 
0.48 
2.0 
0.48 
[84] 
[84] 
EC50 values were determined by TEVC in Xenopus oocytes unless noted otherwise. 
- data not available 
aDetermined by Ca2+ influx assay using HEK cells  
bDetermined in HEK cells 
c spinal cord neurons 
d hippocampal neurons  
N.A. – no activity 
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